Physician Assistant Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Tiffany Cambron

Physician Assistant Virginia Beach, VA Physician Assistant

NPI 1437752367 CMS profile 10655326

5716 Cleveland St Ste 200, Virginia Beach, VA 23462

Open in the dashboard

General payments

$1,365

63 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Tiffany Cambron of Virginia Beach, VA is reported in the CMS Open Payments database as having received $1,365 across 63 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $30 2
2022 General $654 39
2021 General $681 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tiffany Cambron
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Tiffany Cambron were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Tiffany Cambron Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $681 $132 $37–$438 $132
2022 $654 $155 $48–$522 $149
2023 $30 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Janssen Pharmaceuticals, Inc $315 8 payments
  2. Novartis Pharmaceuticals Corporation $303 18 payments
  3. iRhythm Technologies, Inc. $166 2 payments
  4. Amgen Inc. $142 8 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $123 6 payments
  6. Merck Sharp & Dohme Corporation $97 7 payments
  7. E.R. Squibb & Sons, L.L.C. $49 3 payments
  8. Sanofi-Aventis U.S. LLC $39 2 payments
  9. Pfizer Inc. $32 2 payments
  10. Fidia Pharma USA Inc. $30 2 payments
  11. Other $70 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $1,365 63 payments
Products named General payments · program years 2021–2023
  1. XARELTO $315 8 payments
  2. ENTRESTO $303 18 payments
  3. Repatha $142 8 payments
  4. ZIO Patch $137 1 payment
  5. JARDIANCE $123 6 payments
  6. VERQUVO $97 7 payments
  7. LEQVIO $76 5 payments
  8. ELIQUIS Cardiovascular $49 3 payments
  9. MULTAQ $39 2 payments
  10. ELIQUIS Cardiovascular;Metabolic Disease $32 2 payments
  11. Other $129 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

1,608

Median for Physician Assistant: 241

Drug cost

$13,399

Median for Physician Assistant: $4,110

Branded share of claims

9.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 36 $8,066
Oxycodone Hcl Generic 451 $2,417
Tramadol Hcl Generic 449 $1,337
Ondansetron Odt Ondansetron Brand 102 $433
Ondansetron Hcl Generic 135 $324
Amoxicillin Generic 302 $296
Methylprednisolone Generic 33 $165
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 19 $162
Hydromorphone Hcl Generic 25 $129
Clindamycin Hcl Generic 56 $71

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$70,382

Of which drugs: $1,697

Medicare patients

701

Average age 74

Services billed

2,934

453 women, 248 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 30%
Depression 23%
Ischemic heart disease 21%
Chronic kidney disease 19%
Cancer 19%
Osteoporosis 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 150 1,196 $791

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

63 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record